Efficacy and Safety of AS012 in Subjects With Non-segmental Vitiligo
A Phase II, Randomized, Double Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of AS012 in Subjects With Non-segmental Vitiligo
Sponsor: Ache Laboratorios Farmaceuticos S.A.
A PHASE2 clinical study on Non-segmental Vitiligo, this trial is completed. The trial is conducted by Ache Laboratorios Farmaceuticos S.A. and has accumulated 17 data snapshots since 2021. Psychiatric clinical trials are essential for establishing evidence-based treatment standards.
Status Flow
Change History
17 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Apr 2025 — Sep 2025 [monthly]
Completed PHASE2
-
Sep 2024 — Apr 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Apr 2023 — Jul 2024 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
▶ Show 12 earlier versions
-
Nov 2022 — Apr 2023 [monthly]
Active Not Recruiting PHASE2
-
Sep 2022 — Nov 2022 [monthly]
Active Not Recruiting PHASE2
-
Jul 2022 — Sep 2022 [monthly]
Active Not Recruiting PHASE2
-
Jun 2022 — Jul 2022 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Mar 2022 — Jun 2022 [monthly]
Recruiting PHASE2
-
Dec 2021 — Mar 2022 [monthly]
Recruiting PHASE2
-
Nov 2021 — Dec 2021 [monthly]
Recruiting PHASE2
-
Jun 2021 — Nov 2021 [monthly]
Recruiting PHASE2
-
Apr 2021 — Jun 2021 [monthly]
Recruiting PHASE2
-
Mar 2021 — Apr 2021 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jan 2021 — Mar 2021 [monthly]
Not Yet Recruiting PHASE2
-
Aug 2020 — Jan 2021 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Ache Laboratorios Farmaceuticos S.A.
For direct contact, visit the study record on ClinicalTrials.gov .